MaxCyte appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

MaxCyte announced the appointment of Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21. Soleymannezhad will lead global product development and marketing strategy for MaxCyte’s bioprocessing business. The bioprocessing business is anchored by the STx and VLx platforms supporting biotherapeutic research, development and manufacturing using transient expression to produce complex proteins, vaccines and biologics at scale. Soleymannezhad brings almost 20 years of technical, sales and marketing expertise in biomanufacturing, bioprocessing and bioanalysis to his new role. Most recently, he served as Executive Vice President for the Separations and Purification business at Tosoh Bioscience overseeing a team of 140 employees across four global manufacturing, development, and commercial sites. During his tenure at Tosoh, Soleymannezhad was also Vice President of Global Marketing and Business Development and Director of Sales and Marketing Americas and served on the board of Semba Biosciences. Soleymannezhad received a Master of Business Administration in finance from Jones Graduate School of Business at Rice University in Texas after completing his Master and Bachelor of Chemical Engineering at University of Western Ontario’s Faculty of Engineering in Canada.